This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Diseases treated

Authoring team

Non-malignant disease:

  • aplastic anaemia - results in disease free survival in more than 50% of patients
  • thalassaemia
  • sickle cell anaemia
  • immunodeficiency diseases - including severe combined immunodeficiency disease, Wiskott-Aldrich syndrome
  • Gaucher's disease

Malignant disease:

  • acute myeloid leukaemia - high dose chemotherapy or radiotherapy and BMT is potentially curative; allogeneic is generally preferred
  • acute lymphoblastic leukaemia - as standard intensive chemotherapy is so effective, BMT is reserved for special situations such as Philadelphia positive ALL. Allogeneic is usually preferred, as it is associated with a lower rate of relapse
  • chronic myeloid leukaemia - with the introduction of imatinib, allogeneic stem cell transplantation is no longer considered as the first line treatment method in patients with chronic phase of CML (1)
  • chronic lymphocytic leukaemia - allogeneic BMT preferred
  • multiple myeloma - controversial as to whether allogeneic or autologous is the best; standard chemotherapy is rarely curative

Note that BMT is not considered part of standard therapy in the treatment of CLL or multiple myeloma.

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.